trial

Treatment on Iatrogenic Weight Gain and Dyslipidaemia Associated With Olanzapine

NCTId NCT01491490
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Terminated
Enrollment 2 (actual)
Sponsored by GW Research Ltd
Primary completion 2012-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Terminated
Enrollment
2 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2011-10
Primary completion
2012-10
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
GWP42003 : GWP42004 (40:1)

Sponsors

GW Research LtdLead Sponsor

Investigators

6
PIPrincipal Investigator
PIPrincipal Investigator
PIPrincipal Investigator
PIPrincipal Investigator
PIPrincipal Investigator
CIPrincipal Investigator

Sites

0 total

Linked catalysts

1
Treatment on Iatrogenic Weight Gain and Dyslipidaemia Associated With Olanzapine — primary completion2012-10

Facts & assertions

4 sourced
Enrollment
2
Phase
PHASE2
Primary Completion Date
2012-10
Status
TERMINATED
relationships
The graph out of here
drug
GWP42003 : GWP42004 (40:1)
drug
lead_sponsor
GW Research Ltd
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
PI
person
PI
person
PI
person
PI
person